asx:rac

0:12:36

Race Oncology (ASX:RAC) Expands RC220 Clinical Trial to Second Site | Phase 1 Update

0:06:06

Race Oncology on RC220 ethics, 2024 milestones and 2025 outlook

0:07:04

RACE ONCOLOGY (ASX: RAC) | INSANE Growth | ASX Growth Stocks | March 2021

0:02:45

Race Oncology welcomes positive pre-IND meeting for Zantrene

0:33:41

A Speculative Peer M&A Comparison for Value: Race Oncology (ASX: RAC)

0:03:25

Race Oncology poised for observational heart protection breast cancer trial

0:27:35

Race Oncology (ASX: RAC) – Breakthrough Cancer Treatment Discovery

0:10:59

Daniel Tillet from Race Oncology (RAC) - Switzer Small & Micro Cap Conference September 2022

0:00:18

Race Oncology (ASX:RAC): Receives ethics approval from the Bellberry Human Research Ethics Committee

0:08:00

Race Oncology highlights impressive bisantrene clinical data

0:27:43

Race presents at IRD Invest

0:13:32

Race Oncology ASX Small and Mid Cap Conference

0:04:53

Race Oncology advances RNA epigenetics with FTO drug discovery at Monash

0:03:07

ASX:RAC - Race Oncology MD Phillip Lynch on 3AW, 2GB & 6PR Bulls N' Bears Report

0:11:26

Race Oncology's Daniel Tillett details positive preclinical results for Bisantrene in breast cancer

0:04:16

Race Oncology's breakthrough in cancer cell treatment

0:00:52

ASX market open video 11th June 🚀

0:04:56

Race Oncology hits 12-month high with new multiple myeloma findings

0:08:11

Race CEO Daniel Tillett Joins Hot Copper webinar to discuss bringing medical developments to market

0:10:46

Pitt St Research interview with Race Oncology's CEO Phil Lynch and CSO Dr Daniel Tillett

0:22:42

Race Oncology raises $29.7m to fund development of lead anti-cancer drug Zantrene

0:06:49

Race Oncology receives positive results from AML trial of Bisantrene

0:08:05

Race Oncology receives US FDA rare paediatric disease designation for AML treatment

0:01:04

ASX market open video Wednesday 12th June